Abstract. Despite near elimination of Haemophilus infueitzae b (fib) meningitis from several industrialized countries following introduction of conjugate Hib vaccines into infant immunization schedules, Hib remains a major cause of meningitis and pneumonia in resource-poor countries. In Niger, Hib causes nearly 200 cases of meningitis per 100,000 children < one year of age, and > 40% of cases are fatal. We evaluated the immunogenicity of Hib polysaccharidetetanus toxoid conjugate vaccine (PRP-T) administered in the same syringe as diphtheria-tetanuspertussis (DTP) vaccine among infants in Niger. Infants were randomized into group 1 (PRP-T at six, 10, and 14 weeks), group 2 (PW-T at 10 and 14 weeks), or a control group (meningococcal A/C polysaccharide vaccine). By 14 weeks of age, all subjects in groups land 2 had 2 0.15 Fg/ml of anti-PRP antibody, and 82% versus 76% had 1 1.0 Fglml of antibody (P = not significant). By nine months of age the proportion of infants with 2 0.15 and 2 1.0 pglml was group 1 = 97% and 76%; group 2 = 93% and 67%; controls = 10% and 2.6%. Four weeks after the first, second, and third doses of PRP-
1.0 Fglml of antibody (P = not significant). By nine months of age the proportion of infants with 2 0.15 and 2 1.0 pglml was group 1 = 97% and 76%; group 2 = 93% and 67%; controls = 10% and 2.6%. Four weeks after the first, second, and third doses of PRP-T, infants in group 1 showed geometric mean titers (GMTs) of 0.19, 3.97, and 6.09 pg/ml while infants in group 2 had GMTs of 2.40 and 4.41 pglml four weeks after the delayed first and second doses. Both PRP-T groups had significantly higher GMTs at 18 weeks and nine months of age than infants in the control group. The Hib PRP-T vaccine was immunogenic in infants in Niger. The strong response after PRP-T was initiated one month after the first DTP vaccination may reflect carrier priming. Two dose schedules of PRP-T should be given serious consideration, particularly if their reduced cost permits vaccine introduction that would be otherwise unaffordable.
Routine use of Haeinophilus infueiizae b (Hib) conjugate vaccines in infant immunization programs has led to near elimination of Hib meningitis from several industrialized countries.'.* Although H. infcienzae is a major cause of meningitis in developing counties and is associated with high case fatality and substantial neurologic sequelae, Hib vaccines are not routinely used in countries with limited resources.3-6 In countries within the meningitis belt of subSaharan Africa, the contribution of H. in$ueizzae b to childhood meningtis may be 'mecognized since microbio~ogic is typically limited to a few reference hospitals, and cOncem about epidemics of me--importance of specific causes of endemic meningitis.
Review of data regarding bacterial meningitis in Niamey, Niger from 1981 to 1996 identified a minimal estimate for the incidence of meningitis due to H. inJzuenzae of 1951 100,000 children less than one year of age and 52/100,000 children less than five years of age. More than 80% of Hib meningitis cases among children less than five years of age evident by six months of age. The early peak of disease evident in Niamey is typical of other developing countries, and has important implications for design Of suitable Vaccination programs for these Although numerous studies in industrialized countries have demonstrated the immunogenicity, efficacy, and effettiveness of Hib conjugate vaccines agiinst invasive Hib disease: relatively little information is available regarding the response to these vaccines in children in Sub-Sahara Africa, where the presence of nutritional deficiencies, concurrent illnesses such as malaria, or socioeconomic conditions might lead to differences in vaccine-induced protection.'-" Recent demonstration that Hib conjugate vaccines protected infants in the Gambia from severe pneumonia as well as f i b meningitis suggest the enormous impact on childhood morbidity that these vaccines may have in Africa, where acute respiratory infections are a leading cause of childhood deaths.) ' We determined the response among Nigerien infants to an f i b conjugate (tetanus toxoid) vaccine, PW-T (Pasteur Mér-ieux Sérums and Vaccins, Lyon, France) administered in two different schedules in conjunction with routine vaccinations of the Expanded ProPam On Immunization @PI)-w e Compared a standard three-dose primary series with a delayed schedule to assess whether two doses of PFW-T administered with the second and third dose of diphtheria-tetanus-pertusthe three-dose regimen, and could therefore offer a more economical way to protect young children in Africa. Since EPI administration of the first diphtheria-tetanus-whole cell DTP vaccination. Parents gave informed consent to permit their children to participate in the study. Study design. Children enrolled in the study were randomized into one of three groups (Table 1) . Group 1 received three doses of PRP-T at the same time as DTP injections, scheduled for six, 10, and 14 weeks of age. Group 2 also received three doses of PEU?-T, but administered with the second and third DTP injections at 10 and 14 weeks of age, and the last dose at nine months of age, at the visit when measles and yellow fever vaccines were administered. Children in group 3 served as controls. These infants received two doses of meningococcal N C polysaccharide vaccine at six and 14 weeks of age. Jifants in the control group were given three doses of PRP-T vaccine at the end of the study (age nine months), with one month intervals between vaccinations.
Blood was collected by heel, toe, or fingerstick before each vaccination for groups 1 and 2 at six, 10, 14, and 18 weeks, as well as at nine months of age. Subjects in the control group had blood collected at six weeks, 18 weeks, and nine months of age ( Table 1) .
The study sample size was designed to permit followhp of a minimum of 38 children per group.
Reactogenicity. Children in the study were observed in the clinic for 15 min after each vaccination. Local and systemic reactions were evaluated in a sample of children from groups 1 and 3 one day after the first vaccination. Evaluation was conducted by a physician working at Yantala CSMI who was blinded to the study group of the infant.
Laboratory methods. Antibody directed against the polysaccharide PRP was measured by the Fam-type radioimmunoassay (RIA) method and expressed in terms of micrograms per milliliter. The reference serum for these assays used human anti-Hib (CBER/FDA lot 1983; Office of Biological Reagents and References, Food and Drug Administration, Bethesda, MD) containing 70 pg/ml of antibody. Assays were performed at the Clinical Seroimmunology Laboratory of Pasteur Mérieux Sérums and Vaccins on coded specimens. The lower limit of antibody detectable by the assay was 0.07 pglml. The PRP-antibody concentrations of 2 0.15 yglml and 2 1.0 pglml are considered to reflect short-term and long-term protection, respectively.
Statistical analysis. The SAS software version 6.12 (SAS Institute, Cary, NC) was used for the analyses. Proportions of subjects in each study group that reached antibody concentrations 2 0.15 pglml and ? 1.0 yglml at each age were compared using the chi-square test or, where appropriate, Fisher's exact test. A mixed model analysis of variance (ANOVA) was used to examine differences in geometric mean serologic antibody concentrations among the vaccine and control groups. The vaccine and control groups and the serum bleed number accounted for the fixed effects; the random assignment of individuals to one of the three study groups constituted the random effect. The mixed ANOVA was performed taking into account the repeated measures design of this study and the inherent collinearity among bleeds within an individual. A resultant longitudinal data analysis was performed using the MMED procedure in SAS. For a number of specimens, the lower and upper limit of antibody concentrations were not titrated precisely (i.e., the lower limit was < 0.07 pg/ml and the upper limit ranged from > 2.2 to > 22.0 pg/d). An accelerated failure time model was used to calculate geometric mean concentrations and 95% confidence intervals using the LIFEREG procedure in SAS. This method adjusted for the left and right censoring of these data. Ethical approval. This study was approved by the Ethics Committee of the government of Niger as well as by the Institutional Review Boards of the Centers for Disease Control and Prevention (Atlanta, GA) and the World Health Organization (Geneva, Switzerland).
RESULTS
A total of 180 children were recruited for the study (Group 1= 59, Group 2 = 62, Group 3 = 59), 87 (48.3%) of whom were female. The mean age at each visit was recruitment = eight weeks (range = 4-12); second contact = 13 weeks (range = 9-22); third contact = 18 weeks (range = 13-29); fourth contact = 24 weeks (range = 18-38 weeks), and final contact = nine months. Of these, 151 (83.9%) children completed the study. Sufficient sera for RIA analysis were available for 165 subjects at enrollment, 134 (74%) at the fourth contact, and 119 (66%) at the ninemonth visit.
Adverse reactions. No serious adverse reaction was identified in any study subject. There was no difference between the frequency of fever, vomiting, diarrhea, excessive Crying, or refusal to feed between groups 1 and 3. Swelling at the point of injection was more Common among subjects who received the Hib vaccine (4 of 19) than among those who received the meningococcal polysaccharide vaccine (1 of 30) ( p = 0.07, by Fisher's exact test, two-tailed).
Immune response. Table 2 shows the geometric mean titers (GMTs) of anti-PRP antibody at basefine and subsequent visits for each study group. There was no difference between baseline anti-PRP antibody titers between children in the three groups. Children in groups 1 and 2 had significantly higher antibody levels than the control group at the 18-week and nine-month visit.
Infants in group 1 showed increased antibody levels after each dose, with a peak GMT at 18 weeks of 6.09 p g / d (95% confidence interval [CI] = 3.67, 10.09). Subjects in group 2 responded strongly to the first PRP-T dose administered at the 10-week visit, reaching a GMT of 2.40 (95% CI = 1.70, 3.39) four weeks later. Antibody titers at 18 weeks did not differ significantly between groups 1 and 2. By nine months of age, GMTs decreased to 2.14 in children who had received three doses of PRP-T and 1.67 in children who had received two doses. These results did not differ significantly.
The proportion of children in each study group with antibody levels ? 0.15 and ? 1.0 pg/ml is shown in Table 3 .
Prior to vaccination, children in the three groups did not differ in the proportion with antibody levels ? 0.15 or ? 1.0 pg/ml. A s expected, a higher proportion of children in group 1 than group 2 had antibody levels 2 0.15 or 2 1.0 pg/ml at the 10-week visit, when only group 1 infants had previously received PRP-T vaccine. Four weeks after the second PRP-T injection in group 1 and after the first PRP-T injection in group 2, all subjects had antibody levels > 0.15 pg/ d, and a similar proportion (82% and 76%) had levels 2 1.0 p g / d . The proportion of children in group 1 and group 2 with levels ? 0.15 or 2 1.0 pg/ml at subsequent visits did not differ significantly. Additional analyses revealed no effect of the precise age at vaccination or the interval (in weeks) between vaccinations on subsequent PRP antibody levels. There were too few subjects with high baseline PRP antibody to assess Whether maternally acquired antibody to PRP affected response to subsequent PRP-T vaccine.
DISCUSSION
The PRP-T Hib conjugate vaccine administered in the same syringe as the DTP vaccine in conjunction with the routine childhood immunization schedule was imunogenic in infants in Niger. Overall, 86% of the children achieved antibody levels 2 1.0 p g / d four weeks after a primary series of either two or three doses of PRP-T and 71% maintained this level by nine months of age; 99% of the infants had antibody levels 2 0.15 p g / d four weeks after the second Or cird PRP-T immunization and 95% maintained this level at nine months of age. These data suggest that Hib
PRP-T vaccine is likely to provide excellent protection against Hib disease when administered to young infants according to the EPI schedule. There was little difference in the antibody levels at 18 weeks and nine months of age between children who had received two versus three doses of PRP-T vaccine when the two-dose schedule was delayed to begin one month after the first dose of DTP vaccine. Antibody response to Hib vaccines has varied in different studies according to diverse factors, including age at immunization, type of conjugate vaccine, and whether the vaccine is administered in the same syringe as other antigens.'2-1s Response to certain Hib conjugate vaccines varied in different populations, suggesting that factors such as nutrition, pre-existing antibody to Hib or other antigens, or genetic influences could potentially affect immune r e s p o n~e .~~.~~ It is therefore reassuring to find that Hib antibody levels among infants in Niamey vaccinated with PRP-T were comparable with those identified in children in industrialized countries as well as those identified in recent studies of PRP-T vaccine in the Gambia,IoJ1 since this suggests that efficacy against invasive Hib disease in Niger is likely to be comparable with the high levels observed elsewhere.
Given the large burden of Hib disease in sub-Saharan Africa, and the excellent immune response identified in this study as well as those conducted in the Gambia, the potential benefits of routine use of Hib conjugate vaccine among infants in this region are evident.I0J1 However, cost of vaccine has been a major barrier to adoption of Hib conjugate vaccines even among wealthier, transitional economies.21 Although the price of vaccines supplied to the poorest countries is often negotiated through large volume purchases by international donors and may be provided below cost to certain regions, reducing the number of doses necessary for an immunization series could reduce cost, and consequent price, substantially. Our study addressed the question of whether infants immunized with a delayed two-dose schedule of vaccine during the first months of life would have similar protection to infants who received'three doses.
By four weeks after the last vaccination and nine months of age, GMTs against PRP were similar for the three-dose and two-dose groups, with both groups achieving antibody levels significantly higher than those among control subjects who received meningococcal A/C polysaccharide vaccine. The GMT following the first dose of PRP-T in infants vaccinated at 10 weeks of age (2.40 kg/ml) was significantly higher than the GMT obtained after the first dose of PRP-T was administered at six weeks of age (0.19 pg/ml). Although some of this difference may reflect improved response in infants immunized at an older age, the strong response to PFW-T among infants in group 2 may also reflect the response to carrier priming, since infants in this group had received tetanus toxoid included in the DTP vaccine administered at six weeks of age, and may therefore have been primed to have enhanced response to the tetanus toxoid carrier included in the PRP-T vaccine given four weeks later. 22 These data suggest that omitting administration of a dose of PW-T with the first DTP injection should not have adverse consequences on short-and longer-term immune response, at least measured up to nine months of age, or through much of the at-risk period among infants in Niger. Although there may be logistic difficulties associated with scheduling dif-
ferent vaccines for administration at the six-and 10-week visits, these data suggest that where this schedule is feasible, a reduced number of doses of PRP-T should offer comparable protection to infants at lower cost.
An additional concern in considering the optimal number of Hib doses is the magnitude of Hib disease that occurs before the delayed schedule would provide protection, since if this is large, the cost savings of eliminating a dose may be outweighed by the benefits of a three-dose schedule that protects against early disease. Surveillance for Hib meningitis in Niamey during the period 1981-1996 revealed that only 40 (6.5%) of 611 cases of Hib meningitis among children < five years of age occurred in infants < 12 weeks of age; 17 (2.8%) occurred among infants between eight and 12 weeks of age, cases that would potentially be prevented only by the traditional three-dose schedule (assuming two weeks are needed for antibody production following vaccination with the conjugate vaccine). Despite the official EPI vaccination schedule of six, 10, and 14 weeks of age, children in this trial received routine and study vaccines somewhat later (8, 13 , and 18 weeks of age). One potential risk of delaying the first dose of PRP-T is that children in certain areas may not receive their second DTP injection until much later in infancy. Consideration of local circumstances, such as the coverage and timeliness of infant immunizations, can help EPI program managers and policymakers determine whether a delayed, two-dose schedule of PRP-T is appropriate for their setting. Other approaches, such as neonatal or maternal immunization programs, may address the earliest cases of infant Hib disease in areas where these cases constitute an important burden.= We did not evaluate response to a booster dose of Hib conjugate vaccine. Data from the United Kingdom, where no booster dose is used, suggest that in an industrialized country, the primary series is adequate to dramatically reduce Hib meningitis. 22 The earlier onset of Hib disease in developing countries might make a booster dose even less important for these populations, since most disease, 84% in Niamey, occurs by one year of age. However, carriage of Hib is more common among children in developing count1ies.2~ The impact of the infant vaccination series on rates of carriage and disease in older children is not clear, although vaccinating older children had substantial impact on disease rates in younger infants in industrialized countries.'" Because the EPI infrastructure for delivering vaccines in Africa focuses on children less than one year of age, proposing a vaccination schedule that requires a dose administered to older children is problematic. Since most Hib disease occurs before 12 months of age, and exposure to carriers is likely to boost vaccine-induced immunity among children as they age, the potential value of a booster dose of Hib vaccine in developing countries is unlikely to merit the cost and infrastructure development it would entail.
Infants included in this study were typical of those residing in Niger, and probably representative of children throughout sub-Saharan Africa, in terms of nutritional status and exposure to other endemic diseases such as malaria. Vaccine administered in this study, provided in the same syringe as DTP by EPI personnel administering routine immunizations, was well-tolerated and immunogenic. These data therefore extend the observations collected in the Gambia regarding the potential benefits of Hib vaccine in children in Africa" and are probably applicable to other tropical, resource poor areas where Hib disease rates are high.= These findings also suggest that two-dose schedules should be given serious consideration, particularly when the economic savings of limiting the series to two doses would be sufficient to prompt policymakers to introduce Hib vaccines into routine use.
The excellent immune response evident among Nigerien infants suggests that these vaccines could prevent substantial illness in this region. Although much attention is routinely given to meningococcal epidemics, surveillance in Niamey over a six-year period includmg a major epidemic (1994) (1995) revealed that meningitis deaths due to Hib and pneumococcus exceeded those due to meningococcus. Until success is achieved with other approaches to reducing the cost of Hib vaccines, such as through research into economic production of entirely synthetic Hib vaccine or investigations of lower dose formulations,26 reducing the number of injections may be the best means available to permit the largest number of the world's cydren the benefit of protection against .H. infuenzae b disease.
